Alkermes plc (ALKS)

전일 마감가:

$24.88

열려 있는:

$24.83

하루 거래량:

13,773

시가총액:

$4.21B

수익:

$1.66B

순이익/손실:

$355.76M

주가수익비율:

19.86

EPS:

1.24

순현금흐름:

$353.31M

1주 성능:

+1.53%

1개월 성능:

-9.01%

6개월 성능:

+1.32%

1년 성능:

-13.73%

1일 변동 폭

$24.56

$24.83

52주 변동 폭

$22.01

$33.71

Alkermes plc Stock (ALKS) Company Profile

명칭

Alkermes plc

부문

Healthcare (1193)

산업

Drug Manufacturers - Specialty & Generic (4)

전화

353 1 772 8000

주소

Connaught House, 1 Burlington Road, Dublin

직원

2,000

트위터

@alkermes

다음 수익 날짜

2024-05-01

최신 SEC 제출 서류

ALKS's Discussions on Twitter

Alkermes plc Stock (ALKS) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-11-20	재개	JP Morgan	Neutral
2023-10-24	업그레이드	Evercore ISI	In-line → Outperform
2023-10-17	개시	UBS	Neutral
2022-11-03	업그레이드	Piper Sandler	Neutral → Overweight
2022-10-14	업그레이드	BofA Securities	Underperform → Neutral
2022-08-16	개시	Piper Sandler	Neutral
2022-04-22	재개	Goldman	Buy
2022-04-20	개시	Goldman	Buy
2022-01-27	업그레이드	Cantor Fitzgerald	Hold → Overweight
2021-12-01	개시	Citigroup	Neutral
2021-10-07	업그레이드	Jefferies	Hold → Buy
2021-09-02	다운그레이드	BofA Securities	Neutral → Underperform
2020-10-15	업그레이드	Mizuho	Neutral → Buy
2020-07-30	다운그레이드	Goldman	Neutral → Sell
2020-02-14	다운그레이드	BofA/Merrill	Buy → Neutral
2020-02-14	재확인	H.C. Wainwright	Neutral
2020-02-14	다운그레이드	JP Morgan	Overweight → Neutral
2020-02-06	개시	Mizuho	Neutral
2020-01-31	업그레이드	Wolfe Research	Underperform → Peer Perform
2019-09-05	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	업그레이드	Goldman	Sell → Neutral
2019-05-31	개시	H.C. Wainwright	Neutral
2019-05-01	다운그레이드	Citigroup	Buy → Neutral
2018-12-19	다운그레이드	Goldman	Neutral → Sell
2018-12-14	개시	Wolfe Research	Underperform
2018-12-13	다운그레이드	Credit Suisse	Outperform → Underperform
2018-11-05	개시	Piper Jaffray	Neutral
2018-08-07	개시	Stifel	Hold
2018-06-21	다운그레이드	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	개시	B. Riley FBR, Inc.	Buy
2018-05-16	업그레이드	Citigroup	Neutral → Buy
2018-05-11	개시	BofA/Merrill	Buy

모두보기

Alkermes plc 주식(ALKS)의 최신 뉴스

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Zacks Investment Research

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Zacks Investment Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks Investment Research

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

Zacks Investment Research

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Alkermes plc (ALKS) 재무 분석

Alkermes plc (ALKS) 매출 2024

Alkermes plc (ALKS) 순이익 2024

Alkermes plc (ALKS) 현금흐름 2024

Alkermes plc (ALKS) 주당 순이익 2024